GRM5 Gene

<div class="infobox infobo-gene">
<table>
<tr><th>Gene Symbol</th><td>GRM5</td></tr>
<tr><th>Full Name</th><td>Glutamate Metabotropic Receptor 5</td></tr>
<tr><th>Chromosomal Location</th><td>11q14.2</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/2915" target="_blank">2915</a></td></tr>
<tr><th>OMIM</th><td><a href="https://www.omim.org/entry/604474" target="_blank">604474</a></td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000169040</td></tr>
<tr><th>UniProt</th><td><a href="https://www.uniprot.org/uniprot/P41594" target="_blank">P41594</a></td></tr>
<tr><th>Protein</th><td><a href="/proteins/grm5-protein">mGluR5 Protein</a></td></tr>
<tr><th>Protein Family</th><td>Class C GPCR, Group I mGluRs</td></tr>
<tr><th>Expression</th><td>Striatum, Hippocampus, Cortex, Thalamus</td></tr>
</table>
</div>

Overview

The GRM5 gene (Glutamate Metabotropic Receptor 5) encodes the mGluR5 receptor, a member of the Group I metabotropic glutamate receptor family within the Class C G protein-coupled receptor (GPCR) superfamily. mGluR5 is widely expressed throughout the brain with particularly high levels in the striatum, hippocampus, and cerebral cortex. It plays critical roles in synaptic plasticity, learning, memory, motor control, pain perception, and emotional processing.

<div class="infobox infobo-gene">
<table>
<tr><th>Gene Symbol</th><td>GRM5</td></tr>
<tr><th>Full Name</th><td>Glutamate Metabotropic Receptor 5</td></tr>
<tr><th>Chromosomal Location</th><td>11q14.2</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/2915" target="_blank">2915</a></td></tr>
<tr><th>OMIM</th><td><a href="https://www.omim.org/entry/604474" target="_blank">604474</a></td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000169040</td></tr>
<tr><th>UniProt</th><td><a href="https://www.uniprot.org/uniprot/P41594" target="_blank">P41594</a></td></tr>
<tr><th>Protein</th><td><a href="/proteins/grm5-protein">mGluR5 Protein</a></td></tr>
<tr><th>Protein Family</th><td>Class C GPCR, Group I mGluRs</td></tr>
<tr><th>Expression</th><td>Striatum, Hippocampus, Cortex, Thalamus</td></tr>
</table>
</div>

Overview

The GRM5 gene (Glutamate Metabotropic Receptor 5) encodes the mGluR5 receptor, a member of the Group I metabotropic glutamate receptor family within the Class C G protein-coupled receptor (GPCR) superfamily. mGluR5 is widely expressed throughout the brain with particularly high levels in the striatum, hippocampus, and cerebral cortex. It plays critical roles in synaptic plasticity, learning, memory, motor control, pain perception, and emotional processing.

mGluR5 has emerged as a key therapeutic target in [Alzheimer's disease](/diseases/alzheimers-disease) due to its function as a receptor for amyloid-beta (Aβ) oligomers, which drive synaptic dysfunction. The receptor is also central to the pathophysiology of [Parkinson's disease](/diseases/parkinsons-disease), [Fragile X syndrome](/diseases/fragile-x-syndrome), [schizophrenia](/diseases/schizophrenia), and addiction disorders. Recent advances in PET imaging have enabled visualization of mGluR5 in the living human brain, providing new insights into its role in disease and therapeutic response monitoring[@petersen2024][@lucas2024][@song2024].

Structure and Function

Receptor Architecture

mGluR5 shares the characteristic Class C GPCR architecture with GRM1, but exhibits distinct expression patterns and functional properties:

Extracellular
┌─────────────────────────────────────────┐
│ │
┌─┴───────────────────────────────────────┴─┐
│ Venus Flytrap Domain (VFTD) │
│ Residues: 1-600 │
│ Glutamate binding, dimer formation │
└───────────────────────────────────────────┘
┌───────────────────────────────────────────┐
│ Cysteine-Rich Domain (CRD) │
│ Residues: 600-800 │
│ Signal transduction │
└───────────────────────────────────────────┘
┌───────────────────────────────────────────┐
│ 7-TM Domain (Transmembrane) │
│ Residues: 800-1100 │
│ G protein coupling │
└───────────────────────────────────────────┘
┌───────────────────────────────────────────┐
│ C-terminal Tail │
│ Residues: 1100- 1212 │
│ PDZ motifs, phosphorylation sites │
└───────────────────────────────────────────┘
Intracellular

Key Structural Features

• Orthosteric binding site for glutamate (Kd ~10 μM)
• Forms functional dimers
• Allosteric binding sites for modulators

• Connects VFTD to 7TM domain
• Essential for conformational propagation
• Site of disease-associated mutations

• Gq protein coupling
• Allosteric modulator binding sites
• Target for many drug candidates

• PDZ-binding motif (Ser/Thr-Val/Leu)
• Multiple phosphorylation sites
• Protein-protein interaction domains

Signal Transduction

Like mGluR1, mGluR5 couples to Gq/11 proteins, activating the PLCβ signaling cascade:

Downstream Effects

Receptor Regulation

mGluR5 activity is modulated by:

• Phosphorylation: Ser/Thr residues in C-terminal tail
• Desensitization: GRK-mediated phosphorylation and β-arrestin recruitment
• Trafficking: Endocytic recycling and degradation
• Alternative splicing: Generates multiple isoforms
• Protein interactions: Homer, PSD-95, SHANK proteins

Expression Pattern

Brain Region Distribution

| Brain Region | Expression Level | Cell Types |
|--------------|-----------------|-------------|
| Striatum | Very High | Medium spiny neurons |
| Hippocampus | High | CA1-CA3 pyramidal, dentate gyrus granule |
| Cortex | High | Layer 2/3, 5 pyramidal neurons |
| Thalamus | Medium-High | Relay neurons |
| Olfactory Bulb | Medium | Mitral cells |
| Nucleus Accumbens | Medium-High | Medium spiny neurons |
| Amygdala | Medium | Principal neurons |
| Cerebellum | Low | Granule cells (minor) |

Cellular and Subcellular Localization

• Postsynaptic density: Highly localized to excitatory synapses
• Dendritic spines: Enriched in spine heads
• Axon terminals: Presynaptic mGluR5 in some regions
• Non-neuronal: Microglia, astrocytes (lower levels)

Development and Aging

• Developmental expression: Increases postnatally, peaks in adolescence
• Adult expression: Relatively stable
• Aging: Some decline, but less pronounced than mGluR1

Disease Associations

Alzheimer's Disease

mGluR5 has emerged as a critical player in [Alzheimer's disease](/diseases/alzheimers-disease) pathophysiology:

Aβ-mGluR5 Interaction

• Aβ oligomers bind mGluR5: Acts as a functional receptor for synaptotoxic Aβ oligomers
• Pathogenic signaling: Aβ-mGluR5 complexes trigger calcium dysregulation
• Synaptic dysfunction: Accelerated spine loss and synaptic failure
• Memory impairment: Correlates with cognitive decline

PET Imaging Studies

Recent PET studies have visualized mGluR5 in living AD patients:

| Study | Tracer | Finding |
|-------|--------|---------|
| Petersen 2024[@petersen2024] | [(18)F]PSS232 | mGluR5 associated with amyloid deposition and neurodegeneration |
| Lucas 2024[@lucas2024] | Multiple | SV2A-mGluR5 correlation independent of amyloid |
| Song 2024[@song2024] | Multi-tracer | Synaptic density and mGluR5 changes in early AD |

Therapeutic Implications

• mGluR5 antagonists: Block Aβ-mediated toxicity
• mGluR5 modulators: Preserve synaptic function
• Biomarker potential: mGluR5 PET for diagnosis and monitoring

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease):

• Basal ganglia dysfunction: Enhanced mGluR5 signaling contributes to motor impairment
• L-DOPA-induced dyskinesia: mGluR5 upregulation in dyskinetic states
• Neuroprotection: mGluR5 antagonists show promise in models
• D2 receptor interaction: Cross-talk with dopaminergic signaling[@thompson2024]

Therapeutic Targeting

• mGluR5 NAMs: Reduce dyskinesias without affecting therapeutic benefit
• Combined targeting: mGluR1/5 dual antagonists
• Allosteric modulators: Safer pharmacological profiles

Fragile X Syndrome (FXS)

The mGluR5 theory of FXS remains a dominant framework:

Pathophysiology

• Enhanced signaling: Increased mGluR5-mediated translation
• Synaptic plasticity: Dysregulated LTD
• Dendritic spines: Abnormal morphology and density
• Behavioral phenotypes: Intellectual disability, anxiety, hyperactivity

Clinical Trials

| Agent | Phase | Status | Notes |
|-------|-------|--------|-------|
| Mavoglurant (AFQ056) | Phase 2 | Completed | Mixed results |
| Basimglurant (RO5186526) | Phase 2 | Completed | Some benefit |
| ADX-71149 | Phase 1 | Completed | Safety established |

Recent trials continue to explore mGluR5 NAMs for FXS with refined patient selection[@hamilton2024].

Schizophrenia

mGluR5 dysfunction contributes to [schizophrenia](/diseases/schizophrenia) pathophysiology:

• Hypofunction hypothesis: mGluR5 signaling deficits may contribute to cognitive impairment
• NMDAR interaction: Cross-talk with NMDA receptor signaling
• GABAergic modulation: Altered inhibition
• Therapeutic potential: mGluR5 PAMs as antipsychotic agents

Addiction and Reward

mGluR5 plays a key role in reward processing and addiction[@kumar2024]:

• Dopamine-independent effects: Modulates reinforcement learning
• cue-reward learning: Essential for conditioned responses
• Relapse: Role in craving and reinstatement
• Pharmacological targeting: mGluR5 antagonists reduce drug-seeking

Depression and Anxiety

• mGluR5 antagonists: Show antidepressant-like effects
• Stress response: Modulates HPA axis activity
• Rapid-acting effects: Faster than traditional SSRIs in some models

Therapeutic Targeting

Drug Development Landscape

| Approach | Mechanism | Status | Examples |
|----------|-----------|--------|----------|
| NAMs | Allosteric inhibition | Clinical | Mavoglurant, Basimglurant |
| Antagonists | Orthosteric block | Preclinical | LY-341495 |
| PAMs | Allosteric enhancement | Preclinical | CDPPB, VU0360172 |
| PET Tracers | Imaging | Clinical | [(18)F]PSS232, [(11)C]ABP-688 |

mGluR5 Negative Allosteric Modulators (NAMs)

Clinical Candidates:

• Tested in FXS and addiction
• Mixed efficacy in FXS trials
• Generally well-tolerated

• More potent than mavoglurant
• Tested in depression and FXS
• Shows promise in some indications

• Advanced clinical testing
• Improved brain penetration

Positive Allosteric Modulators (PAMs)

Rationale: Enhance mGluR5 function for cognitive enhancement

• CDPPB: First-generation PAM, cognitive enhancement in rodents
• VU0360172: Improved pharmacokinetic properties
• Novel PAMs: Under development for AD and schizophrenia[@davies2024]

mGluR5 PET Tracers

| Tracer | Status | Applications |
|--------|--------|--------------|
| [(11)C]ABP-688 | Clinical | Baseline mGluR5 mapping |
| [(18)F]PSS232 | Clinical | AD, PD, FXS studies |
| [(18)F]FPEB | Clinical | Receptor occupancy |

Challenges in Drug Development

Recent Research Advances (2023-2025)

PET Imaging in Alzheimer's Disease

Three landmark 2024 studies have advanced our understanding of mGluR5 in AD:

Functional Connectivity Rescue

A groundbreaking 2025 study demonstrates:

• AD mouse model: 20-month-old mice show persistent functional connectivity deficits
• mGluR5 modulation: Treatment with BMS-984923/ALX001 (silent allosteric modulator)
• Rescue effects: Reversal of connectivity deficits and synaptic density restoration
• Clinical translation: Potential for AD therapeutic development[@chen2025]

mGluR5 in Neuroinflammation

Research from 2023-2024 reveals:

• Microglial expression: mGluR5 on microglia and astrocytes
• Inflammatory modulation: Regulates cytokine production
• Disease relevance: Altered in AD and PD brains
• Therapeutic targeting: Anti-inflammatory effects of mGluR5 modulation[@yang2023]

mGluR5-Dopamine D2 Receptor Cross-talk

Recent work reveals:

• Basal ganglia interactions: mGluR5 and D2 receptors form functional complexes
• Therapeutic implications: Combined targeting in PD and dyskinesia
• Signal integration: Downstream pathway convergence[@thompson2024]

Key Publications

Animal Models

Knockout Models

• GRM5⁻/⁻ mice: Viable, with subtle behavioral phenotypes
• Conditional knockout: Region-specific ablation
• Humanized mice: Express human GRM5 variants

Transgenic Models

• FXS model (Fmr1 KO): Elevated mGluR5 signaling
• AD model (APP/PS1): Test mGluR5-targeted drugs
• PD model (α-synuclein): Evaluate neuroprotection

Behavioral Phenotypes

| Model | Key Phenotypes | Utility |
|-------|---------------|---------|
| GRM5⁻/⁻ | Reduced anxiety, altered learning | Basic biology |
| Fmr1 KO | Enhanced mGluR5 signaling | FXS studies |
| AD Tg | amyloid pathology | Drug testing |

Interactome and Pathways

Protein-Protein Interactions

| Partner | Interaction Type | Function |
|---------|-----------------|----------|
| Homer | PDZ binding | Scaffolding, signaling |
| PSD-95 | PDZ binding | Synaptic localization |
| Shank | Multiple | Dendritic spine structure |
| D2 Receptor | Heteromer | Signal integration |
| NMDA Receptor | Functional | Synaptic plasticity |

Signaling Network

Brain Atlas Resources

• [Allen Human Brain Atlas - GRM5 Expression](https://human.brain-map.org/microarray/search/show?search_term=GRM5): Gene expression data in human brain
• [Allen Mouse Brain Atlas - GRM5](https://mouse.brain-map.org/search?type=gene&term=GRM5): Mouse brain expression patterns
• [Allen Cell Type Atlas](https://celltype.brain-map.org/): Single-cell expression data

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Fragile X Syndrome](/diseases/fragile-x-syndrome)
• [Schizophrenia](/diseases/schizophrenia)
• [Hippocampus](/brain-regions/hippocampus)
• [Striatum](/brain-regions/striatum)
• [Glutamate Signaling](/mechanisms/glutamate-signaling-pathway)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [mGluR1](/entities/grm1-gene)
• [GRM5 Protein](/proteins/grm5-protein)

External Links

• NCBI Gene: [https://www.ncbi.nlm.nih.gov/gene/2915](https://www.ncbi.nlm.nih.gov/gene/2915)
• UniProt: [https://www.uniprot.org/uniprot/P41594](https://www.uniprot.org/uniprot/P41594)
• Ensembl: [https://www.ensembl.org/Homo_sapiens/ENSG00000169040](https://www.ensembl.org/Homo_sapiens/ENSG00000169040)
• OMIM: [https://www.omim.org/entry/604474](https://www.omim.org/entry/604474)
• UCSC Genome Browser: [GRM5 locus](https://genome.ucsc.edu/cgi-bin/hgTracks?db=hg38&position=chr11%3A88600000-88850000)
• GTEx Portal: [GRM5 expression](https://gtexportal.org/home/gene/GRM5)
• [Allen Human Brain Atlas](https://brain-map.org/)

References